Empagliflozin trial halted after successful outcome in CKD :

An early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).

Related Keywords

, Richard Haynes , William Herrington , Waheed Jamal , Boehringer Ingelheim Eli Lilly , Clinician Scientist Oxford Population Health , University Of Oxford , Boehringer Ingelheim , Population Health Research Unit , Eli Lilly , Health Research Unit , Associate Professor William Herrington , Honorary Consultant Nephrologist , Professor Richard Haynes , Principal Investigator , Corporate Vice President , Cardiometabolic Medicine ,